Concepedia

Gabrielle R. Kolakowski

GR

Statistics

Publications

5

Citations

785

H-Index

5

Active since

2014

Affiliations

Loxo Oncology at Lilly (United States)(Current)

Array BioPharma (United States)

Memorial Sloan Kettering Cancer Center

Eli Lilly (United States)

Gabrielle R. Kolakowski is an author at Loxo Oncology at Lilly (United States) specializing in oncology, pharmacology, and molecular oncology.

Publications per year

2014–2021

5

Publications

5

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake et al. · Cancer Discovery · 2017 · 433 citations · Full text

, , +16

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Benjamin Solomon, Lavinia Tan, Stephen Q. Wong et al. · Journal of Thoracic Oncology · 2020 · 284 citations · Full text

, , +17

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

James F. Blake, John J. Gaudino, Jason De Meese et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 39 citations · Full text

, , +7

Abstract 1464: Pre-clinical characterization of potent and selective next-generation RET inhibitors

Gabrielle R. Kolakowski, Erin D. Anderson, Joshua A. Ballard et al. · Cancer Research · 2021 · 18 citations

, , +15

Abstract P142: Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor

Anke Klippel, Rui Wang, Loredana Puca et al. · Molecular Cancer Therapeutics · 2021 · 11 citations

, , +17

1–5 of 5